Ognomy Sleep, a Buffalo, NY-based end-to-end virtual sleep apnea care network, has raised $20M in Series A funding led by Catalyst Investors and Blue Heron Capital. The platform delivers telehealth consultations, FDA-cleared home sleep tests, and multi-modal treatments including CPAP, oral appliances, Inspire implants, and GLP-1 prescriptions like Zepbound for comorbid obesity. The capital will support nationwide scaling of its AI-enabled care model.
Sleep Tech Funding Follows At-Home Shift
The timing aligns with broader investor interest in sleep medicine as care moves toward at-home diagnostics and remote monitoring. BetterNight raised $33M in a growth round in February 2023, while Wesper secured $9.6M Series A in November 2022 and EnsoData closed $20M Series B in June 2025. Ognomy differentiates through full 50-state insurance coverage and first-mover status on GLP-1 integration for OSA treatment.
Eighty Percent of Cases Remain Undiagnosed
Roughly 80% of the estimated 50M+ American adults with obstructive sleep apnea go undiagnosed, driving annual comorbidity costs of around $150B. Traditional pathways require months of in-person steps, resulting in low adherence rates around 45% for CPAP therapy. Ognomy reports patients seen nine times faster with 62% cost savings versus clinic-based care.
Physician-Built Platform Integrates New Therapies
Founded by sleep physician Dr. Daniel Rifkin, Ognomy compresses the full care journey into roughly one week from home. It stands apart by offering CPAP alongside oral appliances, surgical referrals, and Zepbound prescriptions under one virtual roof, plus Oura Ring data integration for personalized management. This multi-modal approach addresses both apnea and its obesity link, unlike competitors focused primarily on testing or single therapies.
As Dr. Rifkin noted:
"Sleep apnea affects more than one billion people globally, yet access to specialty sleep care remains fragmented, delayed, and inaccessible for far too many patients."
Catalyst and Blue Heron Back National Expansion
Catalyst Investors led the round, with Blue Heron Capital participating; Kapil Desai of Catalyst is joining the board. The syndicate mixes national growth equity with regional backers including University at Buffalo funds. Total funding now reaches $28M, following a $6.8M seed round.
Market Drivers Include Zepbound Approval
The sleep apnea devices market sits at $10-11B in 2026 with projected CAGRs of 7.2-9.6% through 2034, while the home sleep apnea test segment reaches $2.65B. FDA approval of Zepbound for OSA in late 2024 opens new treatment pathways that Ognomy is positioned to capture through its LillyDirect listing and prescribing capabilities.
BetterNight, BlueSleep, and Wesper operate in overlapping spaces but lack Ognomy's combination of nationwide insurance acceptance, GLP-1 prescribing, and 74% CPAP adherence rates.